The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck

Michael E. Kupferman, Mark W. Kubik, Carol R. Bradford, Francisco Civantos, Kenneth O. Devaney, Jesus E. Medina, Alessandra Rinaldo, Sandro J. Stoeckli, Robert P. Takes, Alfio Ferlito

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

From 18% to 35% of cutaneous melanomas are located in the head and neck, and nearly 70% are thin (Breslow thickness ≤ 1 mm). Sentinel lymph node biopsy (SLNB) has an established role in staging of intermediate-thickness melanomas, however its use in thin melanomas remains controversial. In this article, we review the literature regarding risk factors for occult nodal metastasis in thin cutaneous melanoma of the head and neck (CMHN). Based on the current literature, we recommend SLNB for all lesions with Breslow thickness ≥ 0.75 mm, particularly when accompanied by adverse features including mitotic rate ≥ 1 per mm2, ulceration, and extensive regression. SLNB should also be strongly considered in younger patients (e.g. < 40 years old), especially in the presence of additional adverse features. All patients who do not proceed with sentinel lymph node biopsy must be carefully followed to monitor for regional relapse.

Original languageEnglish
Pages (from-to)226-232
Number of pages7
JournalAmerican Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume35
Issue number2
DOIs
StatePublished - Mar 1 2014

Fingerprint

Sentinel Lymph Node Biopsy
Melanoma
Neck
Head
Skin
Neoplasm Metastasis
Recurrence

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck. / Kupferman, Michael E.; Kubik, Mark W.; Bradford, Carol R.; Civantos, Francisco; Devaney, Kenneth O.; Medina, Jesus E.; Rinaldo, Alessandra; Stoeckli, Sandro J.; Takes, Robert P.; Ferlito, Alfio.

In: American Journal of Otolaryngology - Head and Neck Medicine and Surgery, Vol. 35, No. 2, 01.03.2014, p. 226-232.

Research output: Contribution to journalArticle

Kupferman, ME, Kubik, MW, Bradford, CR, Civantos, F, Devaney, KO, Medina, JE, Rinaldo, A, Stoeckli, SJ, Takes, RP & Ferlito, A 2014, 'The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck', American Journal of Otolaryngology - Head and Neck Medicine and Surgery, vol. 35, no. 2, pp. 226-232. https://doi.org/10.1016/j.amjoto.2013.12.004
Kupferman, Michael E. ; Kubik, Mark W. ; Bradford, Carol R. ; Civantos, Francisco ; Devaney, Kenneth O. ; Medina, Jesus E. ; Rinaldo, Alessandra ; Stoeckli, Sandro J. ; Takes, Robert P. ; Ferlito, Alfio. / The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck. In: American Journal of Otolaryngology - Head and Neck Medicine and Surgery. 2014 ; Vol. 35, No. 2. pp. 226-232.
@article{565cf59e6eb04900af0e88e6709ade27,
title = "The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck",
abstract = "From 18{\%} to 35{\%} of cutaneous melanomas are located in the head and neck, and nearly 70{\%} are thin (Breslow thickness ≤ 1 mm). Sentinel lymph node biopsy (SLNB) has an established role in staging of intermediate-thickness melanomas, however its use in thin melanomas remains controversial. In this article, we review the literature regarding risk factors for occult nodal metastasis in thin cutaneous melanoma of the head and neck (CMHN). Based on the current literature, we recommend SLNB for all lesions with Breslow thickness ≥ 0.75 mm, particularly when accompanied by adverse features including mitotic rate ≥ 1 per mm2, ulceration, and extensive regression. SLNB should also be strongly considered in younger patients (e.g. < 40 years old), especially in the presence of additional adverse features. All patients who do not proceed with sentinel lymph node biopsy must be carefully followed to monitor for regional relapse.",
author = "Kupferman, {Michael E.} and Kubik, {Mark W.} and Bradford, {Carol R.} and Francisco Civantos and Devaney, {Kenneth O.} and Medina, {Jesus E.} and Alessandra Rinaldo and Stoeckli, {Sandro J.} and Takes, {Robert P.} and Alfio Ferlito",
year = "2014",
month = "3",
day = "1",
doi = "10.1016/j.amjoto.2013.12.004",
language = "English",
volume = "35",
pages = "226--232",
journal = "American Journal of Otolaryngology - Head and Neck Medicine and Surgery",
issn = "0196-0709",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - The role of sentinel lymph node biopsy for thin cutaneous melanomas of the head and neck

AU - Kupferman, Michael E.

AU - Kubik, Mark W.

AU - Bradford, Carol R.

AU - Civantos, Francisco

AU - Devaney, Kenneth O.

AU - Medina, Jesus E.

AU - Rinaldo, Alessandra

AU - Stoeckli, Sandro J.

AU - Takes, Robert P.

AU - Ferlito, Alfio

PY - 2014/3/1

Y1 - 2014/3/1

N2 - From 18% to 35% of cutaneous melanomas are located in the head and neck, and nearly 70% are thin (Breslow thickness ≤ 1 mm). Sentinel lymph node biopsy (SLNB) has an established role in staging of intermediate-thickness melanomas, however its use in thin melanomas remains controversial. In this article, we review the literature regarding risk factors for occult nodal metastasis in thin cutaneous melanoma of the head and neck (CMHN). Based on the current literature, we recommend SLNB for all lesions with Breslow thickness ≥ 0.75 mm, particularly when accompanied by adverse features including mitotic rate ≥ 1 per mm2, ulceration, and extensive regression. SLNB should also be strongly considered in younger patients (e.g. < 40 years old), especially in the presence of additional adverse features. All patients who do not proceed with sentinel lymph node biopsy must be carefully followed to monitor for regional relapse.

AB - From 18% to 35% of cutaneous melanomas are located in the head and neck, and nearly 70% are thin (Breslow thickness ≤ 1 mm). Sentinel lymph node biopsy (SLNB) has an established role in staging of intermediate-thickness melanomas, however its use in thin melanomas remains controversial. In this article, we review the literature regarding risk factors for occult nodal metastasis in thin cutaneous melanoma of the head and neck (CMHN). Based on the current literature, we recommend SLNB for all lesions with Breslow thickness ≥ 0.75 mm, particularly when accompanied by adverse features including mitotic rate ≥ 1 per mm2, ulceration, and extensive regression. SLNB should also be strongly considered in younger patients (e.g. < 40 years old), especially in the presence of additional adverse features. All patients who do not proceed with sentinel lymph node biopsy must be carefully followed to monitor for regional relapse.

UR - http://www.scopus.com/inward/record.url?scp=84896700326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896700326&partnerID=8YFLogxK

U2 - 10.1016/j.amjoto.2013.12.004

DO - 10.1016/j.amjoto.2013.12.004

M3 - Article

C2 - 24439782

AN - SCOPUS:84896700326

VL - 35

SP - 226

EP - 232

JO - American Journal of Otolaryngology - Head and Neck Medicine and Surgery

JF - American Journal of Otolaryngology - Head and Neck Medicine and Surgery

SN - 0196-0709

IS - 2

ER -